Do you have bladder cancer and have had your bladder removed? If so, you may be able to take part in a research study to determine if patients need additional treatment called immunotherapy to prevent cancer from coming back.

This research study is being done in participants with advanced B-cell malignancies such as some types of lymphomas or leukemias. B-cell malignancies express a protein called the Bruton's tyrosine kinase (BTK), which has been shown to help the tumor cells grow and survive. The investigational drug, AC676, has been designed to recognize the BTK protein, and marks it for destruction. By destroying the BTK protein, the malignancy may be stopped from growing. "Investigational" means the study drug being tested is not approved by the FDA. This is an open-label study, meaning all patients who are eligible to participate will receive study drug. The key purposes of this study are to: ● Test the study drug at different dose levels (dose-escalation) and to determine the highest dose that can be taken without side effects that can't be tolerated (referred to as maximum tolerated dose or MTD). ● Determine what dose of

This study aims to understand how a person's race and where they live affect the quality of breast cancer care they receive. We invite Black and/or African American breast cancer patients and survivors from specific areas of North Carolina to participate in a virtual focus group. The purpose of this focus group is to get your feedback about maps and other tools our team has created to show how breast cancer care quality varies around the state and by race. We also want to hear your experiences seeking care in your area, and your ideas about possible reasons behind the patterns in your area.

The purpose of this study is to test the safety and tolerability of using a new treatment called iC9-CAR.B7-H3 T cells in patients with ovarian, peritoneal or fallopian tube cancer.

To determine if the clinical: molecular primary tumor subtype incongruent rate in metastatic breast cancer is greater than 15% (Objective 1a) and whether the results of a clinical RNA-based molecular subtyping assay alters treatment plans as perceived by the treating physician in at least 10% of metastatic breast cancer patients

This research study is a gene therapy study. In this study, the treatment uses your own blood cells after they are modified (changed) to attack and destroy cancer cells. This research study will test doses of modified blood cells. The study will look at whether each dose is safe, tolerable, and effective in destroying cancer cells. The study will also look at harms and side effects of administering modified blood cells to people with your type of cancer. This treatment is experimental and has not been approved by the Food and Drug Administration (FDA) for treating triple negative breast cancer.

Exercise has been shown to be beneficial for the management of common adverse effects of cancer and its treatment such as fatigue, anxiety, depression, changes in strength and physical function, and sleep disruption. Get Real and Heel provides participants with the opportunity to obtain these benefits, regardless of cancer type and disease stage, and without cost.

This study is being done to answer the following question: Can we extend your life after the diagnosis of your cancer in the stomach, esophagus, or gastroesophageal junction by adding a third chemotherapy drug to the usual combination of two chemotherapy drugs? We are doing this study because we want to find out if this approach is better or worse than the usual approach for treatment of your cancer in the stomach, esophagus, or gastroesophageal junction. The usual approach is defined as care most people get for cancer in the stomach, esophagus, or gastroesophageal junction.

Do you have Stage II or III Breast cancer? If you have enough tissue from your breast cancer diagnosis to send for Mammaprint genomic testing, you may be able to take part in this research study. In this study, we want to learn more about adding an immunotherapy drug, durvalumab, to your chemotherapy treatment. The Mammaprint testing is conducted at no cost to you and the cost of durvalumab is covered.

To find out if the study drug AZD9829 is safe and tolerable and effective in treating blood cancer.